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Unnatural amino acidsThe ability to design and tailor-make antibodies to meet the biophysical demands required by the vast range of
current and future antibody-based applications within biotechnology and biomedicine will be essential. In this
proof-of-concept study, we have for the ﬁrst time tailored human recombinant scFv antibodies for site-speciﬁc
photocoupling through the use of an unnatural amino acid (UAA) and the dock’n’ﬂash technology. Inmore detail,
we have successfully explored the possibility to expand the genetic code of E. coli and introduced the
photoreactive UAA p-benzoyl-L-phenylalanine (pBpa), and showed that the mutated scFv antibody could be
expressed in E. coli with retained structural and functional properties, as well as binding afﬁnity. The pBpa
group was then used for afﬁnity capture of the mutated antibody by β-cyclodextrin (β-CD), which provided
the hydrogen atoms to be abstracted in the subsequent photocoupling process upon irradiation at 365 nm. The
results showed that the pBpa mutated antibody could be site-speciﬁcally photocoupled to free and surface
(array) immobilized β-CD. Taken together, this paves the way for novel means of tailoring recombinant scFv an-
tibodies for site-speciﬁc photochemical-based tagging, functionalization and immobilization in numerous
applications.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The humoral immune response is mediated by antibodies, acting as
highly speciﬁc binders against invading pathogens. This unique binding
speciﬁcity has been exploited in a vast range of antibody-based applica-
tions in biotechnology and biomedicine. The ability to engineer antibod-
ies to meet the biophysical demands required by these applications,
such as speciﬁcity, afﬁnity, and stability [1,2] is critical. Adopting recom-
binant antibody libraries, representing large, renewable sources of high-
performing binders [3,4], will open up new avenues for generating, de-
signing, and tailoring binders with such desired properties [5–7].
Engineering antibodies with improved properties, such as stability,
have traditionally been accomplished by mutating single orL-phenylalanine; Fab, fragment
weight; scFv, single-chain Fv
AA, unnatural amino acids; RT,
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. This is an open access article undercombinations of key amino acid residues [8–10], limiting the building
blocks to the standard 20 amino acids. By generating novel transfer
RNA (tRNA)/aminoacyl-tRNA synthetase pairs, Schultz et al. have suc-
cessfully expanded the genetic code, andmade it possible to genetically
encode for more than 70 unnatural amino acids (UAAs) with novel and
diverse physical, chemical, or biological properties in Escherichia coli
(E. coli), yeast, andmammalian cells [11,12]. These novel building blocks
include ﬂuorescent, glycosylated, metal-ion-binding, and redox-active
amino acids, as well as amino acids with unique chemical and photo-
chemical reactivity [13,14], for review see [15], providing a powerful
method for generating proteinswith novel and/or enhanced properties.
In the case of antibodies, UAA has so far been introduced to full length
IgG and/or fragment antigen-binding (Fab) thereof, to generate e.g. di-
meric antibodies [16],multimeric antibodies [17], antibody–drug conju-
gates [18], and antibody–DNA conjugates [19].
Introducing photoreactive groups in antibodies (proteins) could pro-
vide newmeans for tagging, functionalization, and/or surface immobili-
zation [20–23]. To date, this has mainly been accomplished using
photonic activation of accessible disulﬁde bridges, as illustrated for Fab
antibody fragments [20,21,23]. An alternative route could be to use
UAAs instead, such as the photo cross-linker p-benzoyl-L-phenylalaninethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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[11,13,14]. The ketyl group of pBpa typically reacts with C\H bonds
upon excitation of near-UV light (350–360 nm) resulting in the forma-
tion of an intramolecular C\C covalent bond between reacted pBpa
and target molecule. Based on this, the dock’n’ﬂash technology was re-
cently developed providing the means to speciﬁcally and covalently
photocouple pBpa mutated proteins with site-speciﬁc control based on
a bioafﬁnity mechanism [24]. In more detail, the authors successfully
exploited the afﬁnity docking of the pBpa group at the protein surface
into a β-cyclodextrin (β-CD) host, which were then covalently coupled
in a light-dependent reaction with non-denaturing UVA, using cutinase
(Fusarium Solani Pisi cutinase) as model protein.
In this proof-of-concept study, we have adopted the dock’n’ﬂash
technology and for the ﬁrst time introduced the photoreactive UAA
pBpa residue into a single-chain Fv variable (scFv) antibody, selected
from a human recombinant antibody phage display library, engineered
around a single, constant framework (VH3-23–Vλ1-47) [3]. The results
showed that the pBpa mutated scFv could be expressed with retained
structural and functional properties, including binding afﬁnity, and
that the mutant could be site-speciﬁcally photocoupled to β-CD in
both solution and on-chip (array immobilized). Hence, this opens up
novel routes for tailoring scFv antibodies for photochemical-based
tagging, functionalization, and immobilization in a wide range of appli-
cations, exempliﬁed by, but not limited to, antibody-based microarrays
[5,25].2. Material and methods
2.1. Antibodies
A human recombinant wild-type scFv antibody, denoted a-C1q-wt,
directed against the human complement protein C1q, was selected
from an in-house designed phage display library, as previously de-
scribed [3]. The a-C1q-wt antibody was selected as a model antibody,
since it has been demonstrated to display high speciﬁcity, afﬁnity
(Kd of 2 × 10−10 M), stability, and on-chip microarray functionality
[26–28]. In a similar manner, an endothelial growth factor (VEGF) spe-
ciﬁc scFv antibody, denoted a-VEGF, was selected and used as negative
control.2.2. Site-directed mutagenesis
The position of the pBpa (Bachem, Bubendorf, Switzerland) muta-
tion was chosen according to the following of three criteria: 1) Far
from the complementarity determining regions (CDR) in order to min-
imize any interference with antigen binding. 2)Within an exposed loop
structure in order to maximize the access to pBpa and to minimize the
risk of disturbing the structure of the antibody. 3) The ﬁrst base after
the TAG codon should be an adenine (preferred) or guanine, to mini-
mize the risk of premature termination of the recombinant protein
[29]. To this end, a pBpa mutation site was deﬁned in the variable do-
main of the light chain (VL), Q17, of a-C1q-wt.
Gene encodingpBpamutated a-C1q-wt, denoted a-C1q-mutant, was
generated using QuikChange®Site Directed Mutagenesis kit (Strata-
gene, La Jolla, CA, USA) following the instructions provided by theman-
ufacturer. A complementary forward (5′ TCT GGG ACC CCC GGG TAG
AGG GTC ACC ATC TCT 3′) and reverse (5′AGA GAT GGT GAC CCT CTA
CCC GGG GGT CCC AGA 3′) substitution mutation primer pair was de-
signed, and ordered from Euroﬁns MWG (Edersberg, Germany). The
mutated gene construct carried in the pFab5C.his vectorwas then trans-
formed into competent E. coli XL1-Blue competent cells. Glycerol stocks
were generated and stored at −80 °C until further use. Mutagenesis
was veriﬁed by DNA sequencing (Euroﬁns MWG Operon, Ebersberg,
Germany).2.3. Co-transformation
The a-C1q-mutant-coding plasmid was co-transformed with a
supplementary plasmid, pSUPpBpa-6TRN plasmid encoding the pBpa
tRNA/aminoacyl tRNA synthetase pair, a gift from Dr. Peter Schultz,
Scripps Institute, La Jolla, CA, USA, into the production host TOP10F′
E. coli. Successful clones were re-sequenced (EuroFins MWG Operon)
and stored as glycerol stocks at−80 °C until further use.2.4. Antibody production
The a-C1q-wt, a-VEGF (100 μg/ml ampicillin), and a-C1q-mutant
(100 μg/ml ampicillin and 25 μg/ml chloramphenicol) scFv antibodies
were produced in E. coli (100 ml cultures). In the case of a-C1q-
mutant, the growth medium (2xYT) was supplemented with 1 mM
pBpa [29]. Due to the light sensitivity of pBpa all handling of pBpa-
containing preparations were performed in laboratory areas without
windows and lighting. The produced scFvs were puriﬁed from
either supernatant or periplasmic preparations using afﬁnity chro-
matography on Ni2+-NTA agarose gel (Qiagen, Hilden, Germany).
Bound molecules were eluted with 1 ml 250 mM imidazole, ex-
tensively dialyzed against PBS, and stored at 4 °C, until further use.
The protein concentration was determined by measuring the ab-
sorbance at 280 nm using NanoDrop ND-1000 (NanoDrop Technol-
ogies, Wilmington, USA). The degree of purity and integrity of the
scFvs was evaluated using 10% SDS-PAGE (Invitrogen, Carlsbad,
CA, USA) and Western-blot. In the latter case, the scFv antibodies
were visualized using mouse α-MYC antibody (Zymed, San Francisco,
CA, USA) and horseradish peroxidase conjugated rabbit-anti-mouse
immunoglobulin (Dako Denmark A/S, Glostrup, Denmark), and
developed in a KODAK X-OMAT 1000 processor (Kodak Nordic
AB, Upplands Väsby, Sweden) with Amersham Hyperﬁlm™ ECL
(GE Healthcare).2.5. MALDI-TOF analysis
The antibody preparations were cleaned using ZipTipC4 Pipette Tips
(Millipore, Billerica, MA, USA) before adding the matrix. The tips were
equilibrated by washing with 50% (v/v) acetonitrile (ACN) followed by
0.1% (v/v) TFA. Bound proteins were washed with 0.1% (v/v) TFA, and
subsequently eluted with 70% (v/v) ACN 0.1% (v/v) TFA. The eluates
were mixed 1:1 with matrix (10 mg/ml cinnamic acid, 40% (v/v) ACN,
0.06% (v/v) TFA) and then manually dispensed as double droplets
(1 μl/drop) onto a solid support. Theﬁrst droplet was allowed to dry be-
fore spotting the second. Due to problems purifying the a-C1q-mutant-
CD with ZipTipC4 tips, solutions were directly mixed with the above-
mentioned matrix and spotted. Dried samples were analyzed using
MALDI micro MX ™ (Waters, Milford, MA, USA) and MassLynx™
Software (Waters).2.6. Circular dichroism
The secondary structure and thermostability of the scFv antibodies
were examined using circular dichroism (CD), (J-720 Spectropolarime-
ter (Jasco, Eaton, MD, USA)). The scFvs were dialyzed (MWCO
12-14.000) against PBS for 1–3 days to remove sodium azide. The sam-
ples were scanned at 20 °C in the far UV, 250–200 nm. A temperature
scan from 20 °C to 95 °C with a thermal ramp of 1 °C/min was also per-
formed, and change in molar ellipticity at 218 nm was recorded, with
two data points perminute. Thermal unfolding scans were analyzed as-
suming a two-state equilibrium between native and denatured state,
and the mid-point of the transition, Tm-value (melting temperature),
was estimated.
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A structural homology model was generated for a-C1q-wt using the
Web Antibody Modelling server following the standard guidelines
(http://antibody.bath.ac.uk). The structure was examined and visual-
ized, using PyMOL Molecular Graphics System (Schrödinger, LCC).
A structural model for a-C1q-mutant was generated in PyMOL by ex-
changing Gln17 with pBpa, and by using a database for non-natural
amino acid sidechain rotamers (http://swisssidechain.ch. ID for pBpa:
PBF). A structural model for the inclusion complex of a-C1q-
mutant–β-CD was generated by manual docking in PyMOL.
2.8. Antigen and serum samples
Puriﬁed C1q was purchased from ElectraBox Diagnostica (Tyresö,
Sweden). Puriﬁed C3 was obtained from Sigma (St. Louis, MO, USA).
Two well-characterized (de-identiﬁed) human serum samples, includ-
ing a large pool of normal human sera and a C1q complement-
deﬁcient serum samples, i.e. a well-characterized sample with signiﬁ-
cantly reduced C1q level, were used as control samples (Skåne Univer-
sity Hospital, Lund, Sweden).
2.9. Labeling of antigen and serum samples
Pure C1q was labeled with Alexa-647 (Molecular Probes, Eugene,
OR, USA) at a molar ratio of 10:1 dye:protein in 40% (v/v) glycerol in
PBS, and incubated on ice for 5 h, with careful mixing every 20 min.
Next, labeled C1q was extensively dialysed against 40% (v/v) glycerol
in PBS, aliquoted, and stored at−80 °C until further use.
The serum samples (about 90 mg/ml) were biotinylated using
EZ-Link Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL, USA) according to
previously optimized labeling protocol for serum proteome [26,28].
Brieﬂy, the serum samples were labeled at a molar ratio of biotin: pro-
tein (15:1), and unreacted biotin was removed by extensive dialysis
against PBS (pH 7.4). Finally, the samples were aliquoted and stored
at−20 °C until further use.
2.10. Generation of β-CD functionalized slides
The 1st generation of β-CD functionalized slides was generated.
Quartz slides (25 × 76 × 1 mm) were purchased from SPI supplies
(Wester Chester, USA). β-CD was obtained from Wacker Chemie AG
(Munich, Germany) and dried at 110 °C in vacuum for 24 h prior to use.
Prior to silanization the quartz slides were cleaned with a solution
of HCl/MeOH (1:1) for 30 min, followed by 30 min in H2SO4 and then
rinsed with milli-Q. In order to increase the number of surface
silanols, the slides were exposed to a 6:1:1 solution of milli-Q:HCl:
H2O2 for 10 min at 80 °C, extensively washed with milli-Q, dried
under a mild stream of nitrogen and ﬁnally dried for 4 h at 110 °C in a
vacuum oven. For silanization, the slides were covered with 0.5%
3-glycidyloxypropyl-trimethoxysilane in dry toluene and left to react
overnight at room temperature (RT) under a nitrogen atmosphere.
After silanization, the slides were rinsed extensively with toluene and
EtOH, dried under amild stream of nitrogen and if not used immediate-
ly, kept under argon until further use.
The sodium salt of β-CDwas prepared by adding 140mg (40mM) of
oil-free NaH and 100 μl tert-butyl alcohol to a pre-dried 250ml reaction
ﬂask with 1 g dry β-CD (6 mM) in 150 ml dry N,N-dimethylformamide
(DMF) under stirring and nitrogen atmosphere for 0.5 h. Next, the solu-
tionwas ﬁltered under nitrogen atmosphere to remove excess NaH. The
solution containing the β-CD sodium salt was then transferred to a pre-
dried 250 ml reaction ﬂask, heated to 80 °C and then transferred to a
preheated reaction dish holding the epoxy functionalized quartz slides.
The grafting reaction was allowed to proceed overnight at 80 °C under
nitrogen atmosphere and was then washed with DMF, toluene, EtOHand milli-Q, in this order and ﬁnally dried under mild stream of
nitrogen.
2.11. Antibody microarray—black polymer Maxisorb slides
Antibody microarrays were produced by dispensing single droplets
(about 300 pl) of a-C1q-wt, a-C1q-mutant (±β-CD), a-VEGF (negative
control), and PBS (negative control) onto black polymerMaxisorb slides
(Nunc A/S, Roskilde, Denmark) using the non-contact printer
SciFLEXARRAYER S11 (Scienion AG, Berlin, Germany) [26,28]. The
spotting reagents were arrayed in eight replicates per subarray and in-
dividual subarrays were created using a hydrophobic pen (Dako
Denmark A/S). All incubation steps were performed at RT in a humidity
chamber, protected from light. First, the arrays were blocked with
5% (w/v) fat-free milk powder (Semper AB, Sundbyberg, Sweden)
in PBS o/n (PBS-M). The arrays were washed three times with
0.05% (v/v) Tween-20 in PBS (PBS-T) and incubated with biotinylated
serum sample or directly labeled C1q (0.01 to 100 nM) for 1 h. All
serum samples were diluted 1:10 (resulting in a total serum dilution
of 1:450, corresponding to about 0.2 mg/ml) in 1% (w/v) fat free milk
powder and 1% (v/v) Tween-20 in PBS (PBS-MT). Next, the arrays
were washed three times with PBS-T. Any subarrays incubated with bi-
otinylated serum samples were incubated with 1 μg/ml Alexa-647-
conjugated streptavidin (Invitrogen) diluted in PBS-MT for 1 h. Finally,
the arrays were washed three times with PBS-T and one time with
PBS and directly dried under a stream of nitrogen gas and immediately
scanned.
2.12. Antibody microarray—β-CD-functionalized slides
Antibody microarrays (a-C1q-wt, a-C1q-mutant, and a-VEGF (nega-
tive control) were prepared by manually dispensing 1 to 5 μl on pre-
chilled (4 °C) β-CD functionalized slides and incubated for 1 h at 4 °C
to allow for non-covalent inclusion complex formation (between pBpa
mutated protein and surface immobilized β-CD). Photo-immobilization
(covalent coupling) (dock’n’ﬂash technology [24])was achievedby plac-
ing the slides directly on the pre-chilled 10W low-pressure mercury arc
UVA lamp (USHIO, Cypress, CA) and illuminating them at 365 nm for
15 min at 4 °C. Unbound proteins were removed by washing with
0.5% (w/v) CHAPS in PBS for 4 h at 4 °C. The microrarrays were then
washed once with PBS-M, and then blocked overnight in PBS-M. Next,
the slides were handled as described under 2.11.
2.13. Reverse antibody microarrays
Reversed antibody microarrays were produced by dispensing single
droplets (about 300 pl) of 0.1 mg/ml pure antigen (C1q and C3) onto
black polymer Maxisorb slides (Nunc) using the non-contact printer
SciFLEXARRAYER S11 (Scienion). The antigens were spotted in eight
replicates per slide. Individual subarrays were created using a hydro-
phobic pen (Dako Denmark A/S). All incubation steps were performed
at RT for 1 h in a humidity chamber protected from light. The microar-
rays were blockedwith PBS-M, washedwith PBS-MT, and subsequently
incubated with 1 μg/ml scFv (a-C1q-wt and a-C1q-mutant). After
washing, the arrays were incubated with 0.2 μg/ml α-His mouse IgG
in PBS-MT for 1 h. Subsequently, the arrays were incubated with
0.2 μg/ml Cy5-conjugated AfﬁniPure F(ab′) goat-anti-mouse IgG (Fcy
fragment speciﬁcity) in PBS-MT. After a ﬁnal washing with PBS-T, the
arrays were rinsed with pure PBS, dried under a stream of nitrogen
gas and immediately scanned.
2.14. Scanning of antibody microarrays
All antibody arrays were scanned using a confocal microarray scan-
ner (Perkin-Elmer Life & Analytical Sciences) at 5 or 10 μm resolution,
using three different scanning settings (70% PMT gain and 70% laser
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quantiﬁed using the ﬁxed circle method by ScanArray Express software
V4.0 (Perkin Elmer Life & Analytical Sciences). The local background
was subtracted and to compensate for possible local defects, the two
highest and the two lowest signal intensities were automatically ex-
cluded, and each data point represents themean value of the remaining
four replicates. For spots displaying saturated signal, values from lower
scanning settings were chosen. Only data generated using identical
scanner settings were compared.
2.15. Photo-cross-linking of a-C1q-mutant to β-CD in solution
Photo-cross-linking of a-C1q-mutant and β-CD in solution was
performed by mixing the antibodies (1:1) with 2 to 5 mM β-CD in PBS
in glass vials. The mixture was incubated for 1–2 h at 4 °C, and subse-
quently illuminated for 20 min at 365 nM at 4 °C with a 10 W low-
pressure mercury arc UVA lamp (USHIO). The reaction mixtures were
stored at 4 °C prior to use. The non-mutated wild type antibodies,
a-C1q-wt and a-VEGF, were used as negative controls.
2.16. Binding afﬁnity
The binding afﬁnity, in terms of apparent Kd, was determined for
a-C1q-wt and a-C1q-mutant using antibodymicroarrays on black poly-
mer Maxisorb slides (see Section 2.11). The antibodies were dispensed
in 24 replicates, and visualized by adding directly labeled C1q (see
Section 2.9). First, the amount of antibody was titrated (0.025 to
0.2 mg/ml) in order to deﬁne the optimal concentration (0.09 mg/ml)
of antibody to reach Bmax (the maximum speciﬁc binding) withoutA
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Fig. 2. Sequence analysis andprotein expression of pBpamutated scFv. (A)DNA sequences and corresponding protein sequences of a-C1q-wt and a-C1q-mutant. TAG represents the amber
codon used to encode for pBpa. (B) SDS-PAGE and (C) western-blot analysis of a-C1q-wt and a-C1q-mutant. (D) MALDI-TOF MS analysis of a-C1q-wt and a-C1q-mutant. (E) Protein
expression analysis (3 batches in Top10F’ E. coli) of a-C1q-wt vs. a-C1q-mutant puriﬁed from periplasmic preparations. (F) Protein expression analysis (4 batches in Top10F′ E. coli) of
a-C1q-wt vs. a-C1q-puriﬁed from supernatant preparations.
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Sequence analysis conﬁrmed the successful introduction of the
amber codon, TAG, encoding for pBpa in position 17 in FW-1 of VL
(Fig. 2A). Providing the Top10F′ E. coli protein machinery with the
matching unnatural tRNA/aminoacyl-tRNA synthetase pair and pBpa,
the SDS-PAGE (Fig. 2B) and Western blot analysis (Fig. 2C) showed
that a dominant protein product with an apparent molecular weight
(MW) of about 30 kDa was produced for both a-C1q-wt (theoretical
MW of 28,345 Da) and a-C1q-mutant (theoretical MW of 28,468 Da)
(Fig. 2B). Further, the introduction of pBpa was also conﬁrmed using
MALDI-TOF MS, demonstrating that the molecular weight of the domi-
nant antibody peak (28,333 vs. 28,443 Da) had increased about 110 Da
upon introduction of the Q17pBpa mutation (theoretical MW increase
123 Da) (Fig. 2D).
Next, analysis of protein expression (3 to 4 independent batches of
100 ml cultures) showed that pBpa mutated scFv could be expressed
in Top10F′ E. coli, and be puriﬁed fromboth periplasmic (Fig. 2E) and su-
pernatant (Fig. 2F) preparations using afﬁnity chromatographyonNi2+-
NTA. Compared to the wild-type scFv, the average production yieldswere lower (69%) based on periplasmic preparations (0.65 mg/ml vs.
0.94 mg/ml; 1.0 ml fractions), but more similar when based on
supernatant preparations (0.20 mg/ml vs. 0.16 mg/ml; 1.0ml fractions).
Focusing on the periplasmic preparations, which gave the apparent-
ly best production yield, three additional independent production
batches were produced. Again, the data showed that the yield of
the pBpa mutated scFv was lower (in average 73%) than that of the
wild-type antibody.3.3. Structural analysis of pBpa mutated scFv
In an attempt to investigate the structural impact of the pBpa muta-
tion on the scFv antibody structure, circular dichroism (CD) measure-
ments were performed on both the a-C1q-wt and a-C1q-mutant. First,
the overall secondary structure was compared by recording the CD
wavelength spectra (200–250 nm) at 20 °C (Fig. 3A). Similar curves
were observed for both mutated and wild-type scFv, with typical
shape and negativemaximummolar ellipticity at about 218 nm, charac-
teristic for the dominant anti-parallel β-sheet structure found in native
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tained in the pBpa mutated scFv.
Next, the structural thermo-stability of scFv in solution was de-
termined for a-C1q-wt (Fig. 3B) and a-C1q-mutant (Fig. 3C), using
thermal scans from 20 to 95 °C monitored at 218 nm. In both
cases, a single apparent cooperative unfolding transition was ob-
served, although with different characteristics. For a-C1q-wt, the
transition from native to denatured state was sharp starting at
67 °C and ending at 75 °C, whereas for a-C1q-mutant the transition
endpoints were at 67 °C and 89 °C. In addition, a more noticeable
increase in ellipticity characterized by a “drop” in the scan atA
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To compare the binding afﬁnity and functional activity of pBpa mu-
tated vs. wild-type scFv, conventional antibody microarrays (binding
afﬁnity/on-chip activity—the antibodies were spotted onto slides, and
soluble antigen was applied in serial dilutions) and reverse-phase anti-
bodymicroarrays, or antigenmicroarrays (activity in solution—the anti-
gen was spotted onto slides, and soluble antibodies was applied), were
produced and analyzed (Figs. 4 and 5).
First, the apparent binding afﬁnity (Kd) was determined by
analyzing serial dilutions of directly labeled C1q (Fig. 4). The results
showed that the a-C1q-wt and a-C1q-mutant scFv antibodies
displayed similar Kd values, 2.0 and 3.1 nM, respectively. Hence,
the data implied that the UUA pBpa could be introduced into the
framework of the scFv antibody without impairing the binding
afﬁnity.Targeting a serial dilution of pure antigen (C1q), the antibodymicro-
array analysis showed that arrayed a-C1q-wt and a-C1q-mutant
displayed similar reactivity pattern and degree of activity as reﬂected
by the observed signal intensities (Fig. 5A and B). In both cases, the
limit of detection was below 10 pM pure C1q. The technical reproduc-
ibility of the antibody array-based assay (a-C1q-wt vs. a-C1q-mutant),
including spot-to-spot (CV of 1.9% vs. 2.2%), array-to-array (CV of 18%
vs. 17%), and slide to-slide (R2 of 0.99 vs. 0.84) was found to be similar
(Fig. 5C). Noteworthy, similar reactivity patterns were also observed
for both antibody clones targeting serial dilutions of crude biotinylated
serum containing C1q (Fig. 5D), indicating that the functional activity
of the pBpa mutated scFv was retained. The limit of detection was
below×4500 dilution of crude serum (b ~90 pMC1q).Most important-
ly, no signals were observed for either of the two antibody clones
targeting a C1q deﬁcient serum sample, indicating high and retained
speciﬁcity. The fact that one of the negative controls, a-VEGF, gave a
2171L. Petersson et al. / Biochimica et Biophysica Acta 1844 (2014) 2164–2173positive signal (×450 dilution only) could be explained by the fact that
the serum sample contained VEGF.
In the case of the reverse-phase antibody microarrays, targeting
pure arrayed C1q, lower signals intensities were observed for the
a-C1q-mutant vs. a-C1q-wt analyzed at two different concentrations
(Fig. 5E and F), indicating that the pBpa mutated scFv displayed lower
functional activity in solution. The technical reproducibility of the
reverse-phase antibody arrays (a-C1q-wt vs. a-C1q-mutant), including
spot-to-spot (CV of 6.5% vs. 3.2%) and slide-to-slide (different days)
(CV of 12% vs. 15%) was found to be in the same range (Fig. 5C).
3.5. Dock’n’ﬂash technology—photocoupling of pBpa mutated scFv to β-CD
Finally, we investigated whether pBpa mutated scFv could be
photocoupled to β-CD in both solution and to β-CD functionalised
quartz slides using the dock’n’ﬂash technology (Fig. 6).
First, β-CD (MW of 1135 Da) was mixed with either a-C1q-wt or
a-C1q-mutant and exposed to light at 365 nm. MALDI-TOF MS analysis
showed that the wild-type scFv was, as expected, not photocoupled to
β-CD (Fig. 6A). In contrast, the MS analysis showed that the MW of0
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were used for all three spots. Signal intensities for replicate spots/arrays are shown.the pBpa mutated scFv increased by 1,112 Da, conﬁrming the site-
speciﬁc photocoupling to β-CD (Fig. 6B). The yield of photocoupled an-
tibody was apparently about 50% in the experimental conditions which
were used.
The on-chip functionality of arrayed a-C1q-mutant was then deter-
mined before and after photocoupling to β-CD, targeting both pure la-
beled C1q (Fig. 6C and D) and crude, biotinylated serum containing
C1q (Fig. 6E and F). Using the activity of wild-type scFv as a reference,
the microarray data showed that the pBpa mutated scFv displayed sim-
ilar activity whether or not it had been coupled to β-CD, indicating that
the photocoupling had no, or only minor, effects on the on-chip func-
tionality. A structural model of β-CD is shown in Fig. 6G, outlining the
hydrophobic cavity created, into which pBpa will bind with moderate
afﬁnity to form an inclusion complex.
Next, the a-C1q-wt and a-C1q-mutant were manually dispensed
onto the 1st generation of β-CD coated quartz slides and exposed to
light at 365 nm (Fig. 6H). After washing, the slides were incubated
with a crude, biotinylated serum sample containing C1q. The results
showed that high signal intensities were only observed for the a-C1q-
mutant antibody, while the spots with a-C1q-wt displayed signalG
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ground signals. Hence, the data showed that pBpa mutated scFv, but
not wild-type scFv, had been successfully photocoupled to β-CD coated
quartz slides using the dock’n’ﬂash technology.
4. Discussion
In this conceptual study, we have for the ﬁrst time tailored human
recombinant scFv antibodies for site-speciﬁc photocoupling through
the use of UAAs and dock’n’ﬂash technology. In more detail, we have
successfully introduced the photoreactive UAA pBpa, and showed that
the mutated scFv antibody could be expressed in E. coli with retained
structural and functional properties, including binding afﬁnity, and
that it could be speciﬁcally photocoupled to free and surface (array)
grafted β-CD after inclusion complex formation.
The 7-membered sugar ring of β-CD can be topographically repre-
sented as a toroid with the larger and smaller openings of the toroid ex-
posing the solvent secondary andprimary hydroxyl groups, respectively
[30]. The cavity ofβ-CDwill be hydrophobic, or at least considerably less
hydrophilic than the aqueous environment, and thus be able to host
other hydrophobic molecules. The pBpa mutated scFv (guest) and
β-CD (host) will form an inclusion complex with moderate afﬁnity,
and NMR analysis has indicated that the entire benzophenone ring
might enter the cavity [24]. In the subsequent photocoupling step,
β-CD will provide the hydrogen atoms to be abstracted. The yield of
in-solution photocoupled antibody was apparently about 50% in the ex-
perimental conditions, which were used here, leaving room for im-
provements. Still, similar yields were observed when photocoupling
cutinase in similar conditions [24], and the equilibrium could e.g. reﬂect
that the photoirradiationwas not efﬁcient enough (re-optimized proto-
colwarranted) and/or the afﬁnity of the pBpa–β-CD complex formation.
In future efforts, the moderate afﬁnity of the initial inclusion complex
formation might be improved by substituting the secondary hydroxyl
groups on the wider rim facing the protein surface in a manner to
match the properties of the amino acids ﬂanking pBpa.
In comparison, light-induced immobilization of (recombinant) Fab
antibody fragments to biosensor surfaces have previously been accom-
plished [20,21,23]. However, this approach was based on photoreduc-
tion of solvent-accessible disulﬁde bridges via the photoactivation of
native tryptophan or tyrosine residues in full IgGs or Fab fragments.
Consequently, this approach necessitated lower,more energetic and po-
tentially damaging wavelengths (270–290 nm), and was not speciﬁc to
a single amino-acid residue. In addition, disulﬁde photoreduction is not
compatible with the structural features of scFv designs [1]. In this con-
text, it might be of interest to note that we have designed recombinant
scFv antibodies carrying a terminal cysteine-tag available for immobili-
zation and tagging etc, but the production yields of these novel scFv de-
signs were unsatisfactory (Wingren et al., unpublished observations).
Furthermore, while traditional epitope tags, such as the His6-tag carried
by our scFv antibodies,might be explored to speciﬁcally functionalize an
antibody, the His6-tag would only provide low-/medium-afﬁnity bind-
ing. Covalent binding or high afﬁnity binding is essential in order to
avoid dissociation, which could impair the setup. Although direct mod-
iﬁcations, such as biotinylation, could beutilized to providehigh-afﬁnity
binding (to streptavidin), achieving site- and mono-speciﬁc biotinyl-
ation is challenging, unless UAA with pendant biotin [15] or the so-
called Avi-tag (a 13 amino acid peptide tag enabling site-directed bio-
tinylation) [31] are explored. But in any case, such an approach would
not be compatible with setups targeting biotinylated samples, which
is the case in many antibody microarray-based platforms, including
those utilized by our group.
Tailoring the structural and functional properties of antibodies to
meet the biophysical demands of various applications, exempliﬁed but
not limited to antibody-based microarrays [5,25], is critical. In this
context, it should be noted that we have used in-house designed
human recombinant scFv phage display libraries as probe source forour applications [3] (Persson et al., unpublished data). Noteworthy,
compared to other scFv antibody libraries [4], our libraries are
engineered around a single, constant framework (predominantly
VH3-23 and Vλ1-47). These variable domains, VH and VL, were carefully
selected, based on the excellent structural and functional properties
displayed by the domains, both stand-alone as well as when paired to-
gether [1]. This library design is a key feature, since all the antibody
clones (N1 × 1010) are structurally identical, differing only in their
CDR-regions, i.e. the antigen-binding sites. In turn, this means that
i) the antibodies will display biophysical properties as similar as possi-
ble, and that ii) a re-design (optimization) (e.g. point mutation) of the
scaffold can simultaneously be pin-pointed for and introduced to all li-
brary members [5]. Through traditional antibody engineering ap-
proaches, we have also identiﬁed novel framework point mutations
that inﬂuenced the structural and functional stability of the scFv anti-
bodies, taking the ﬁrst steps towardmicroarray adapting the antibodies
by molecular design [5] (Nordström et al., unpublished observations;
Wingren et al., unpublished observations).
Expanding the genetic code of E. coli through the use of UAAs opens
up entirely new avenues for exploring novel building blocks to tailor
antibodies [16–19], and proteins in general [11–15], with the desired
property, or properties, not normally found in proteins. The introduc-
tion of photoreactive groups, such as pBpa, combined with a β-CD
host and the dock’n’ﬂash technology [24], paves the way for
photochemical-based tagging, functionalization and immobilization in
a vast range of applications. In this study, this was exempliﬁed by im-
mobilization to the 1st generation of in-house designed β-CD function-
alized quartz slides, which in the long-term run could enable crude
antibody preparations to be puriﬁed, coupled, enriched, and speciﬁcally
orientated in a one-step procedure directly on the array surface (afﬁni-
ty-on-a-chip). Additional work will be required in order to optimize the
β-CD functionalized for array-based applications. Adopting such
afﬁnity-on-a-chip approaches, recent work has shown that the perfor-
mance of antibody (protein)microarrays produced using afﬁnity direct-
ed immobilization vs. standard coupling was in many cases superior
[32,33]. This type of photochemistry could also be explored to immobi-
lize antibodies (proteins) in self-assembly array setups, i.e. array plat-
forms where the antibodies (proteins) are expressed directly on the
array in each spot location using cell-free in situ translation from pre-
printed DNA [34–37]. Other exciting future efforts could be to tag the
antibodies with β-CD-DNA and use them as building blocks in self-
addressable antibody array setups [38,39] (Wingren et al. unpublished
observations). In more detail, the antibodies are then equipped with
unique zipcode tags, based on e.g. DNA, and when added to the array
in bulk, the antibodies will ﬁnd their way on their own to their unique
address (spot) on the array composed of e.g. complementary DNA. In
this context, it might of interest to note that Kazane et al. have designed
site-speciﬁc Fab-DNA conjugates through the use of another UAA, p-
acetylphenylalanine, with the aim to perform speciﬁc and sensitive
immune-PCR [19].
Re-designing any protein structure and introducing a mutation,
using either any of the 20 standard amino acids or the +70 UAAs as
building blocks, might impair the structural and functional properties
of the target protein. In this study, only minor adverse effects were ob-
served. With respect to the observed differences in structural proper-
ties, additional experiments will be required in order to explain the
effects on thermal stability (Tm-value) and unfolding transition, as
well as the potential implications thereof. Due to calibration issues,
the molecular weights estimated using MALDI-TOF MS consistently ap-
peared to be about 10–20 Da lower than the theoretically calculated
values. Notably, the non-annotated peak (~27,500 Da) observed in the
MS run of the antibody–pBpa–CD complex was present in both the
wild-type and pBpa mutated antibody preparations, but the proportion
was apparently lower. This might be inﬂuenced by the fact that the
complex was analyzed at a signiﬁcantly lower antibody concentration.
This peak has not been observed in MS analysis of corresponding
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work, why it cannot be explained by a by-product of photoreaction,
like polypeptide cleavage (Wingren et al., unpublished data). In this
context, it might be of interest to note that the use of wavelengths
above 340 nm for photoexcitation should considerably minimize any
potential photodamage to native amino acids, tryptophan in particular.
In future efforts, the site of mutation will be addressed in order to min-
imize any potentially unfavorable effects on the protein production,
structure, binding, and function, as well as optimize the accessibility of
pBpa for photocoupling. Adopting a rational design strategy, we will
continue to explore other positions located in exposed loops of both
VH and VL, as far as possible from the antigen binding-site. Positions
close to the C-terminal afﬁnity tagwill also be exploited. In addition, ad-
ditional antibody clones will be mutated in order to reveal and scruti-
nize any clone-dependent behavior.
Taken together, in this pilot study, we have demonstrated the feasi-
bility for designing and producing recombinant scFv antibodies carrying
UAA with retained structural, functional and binding properties. By in-
troducing the photoreactive pBpa group, we tailored the recombinant
antibodies for site-speciﬁc photocoupling using the dock’n’ﬂash technol-
ogy. In the long-term run thiswill pave theway for photochemical-based
tagging, functionalization, and/or immobilization in a wide range of
protein-based applications.
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